Design Therapeutics, Inc. (DSGN) stock
Close on Nov 12, 2026Market cap $662.11MP/E –Yield –
Design Therapeutics, Inc. reported revenue of $0 for the twelve months to Sep 30, 2026. Free cash flow was -$59.37M. At the latest close the market valued the company at $662.11M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $662.11M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.27
- Dividend yield
- –
- Free cash flow yield
- -8.97%
Fundamentals
- Revenue
- $0
- Net income
- -$74.09M
- EPS, diluted
- -$1.20
- Free cash flow
- -$59.37M
- Book value per share
- $3.21
- Diluted shares
- 63M
Trading
- Next earnings
- Mar 8, 2027 (estimated, during market hours)
- Previous close
- $10.77
- Open
- $10.61
- Day's range
- $10.27 – $10.88
- Volume
- 502,504
- Average volume (20 days)
- 393,676
- Index membership
- Russell 2000 (since Jun 2021), Russell 3000 (since May 2021)
- Beta (5 years)
- 1.69
- 52-week range
- $6.81 – $17.25
- RSI (14 days)
- 46.5
- Volatility (1 year)
- 70.5%
- Relative volume
- 0.89×
- WACC
- 13.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | DSGN | S&P 500 | Difference | DSGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.0% | -2.7% | −0.3 pts | ||
| 3 months | -27.8% | -1.7% | −26.1 pts | ||
| Year to date | +12.8% | +11.9% | +0.9 pts | ||
| 1 year | +39.0% | +12.0% | +27.0 pts | ||
| 3 years | +426.4% | +78.2% | +348.2 pts | +74.0% | +21.2% |
| 5 years | -47.1% | +73.2% | −120.4 pts | -12.0% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Design Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Design Therapeutics
Pharmaceutical Preparations
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutic candidates called GeneTAC molecules. These chimera molecules are designed to treat monogenic degenerative diseases caused by inherited nucleotide repeat expansion mutations, which lead to either protein deficiencies or toxic gene products. The company's lead investigational programs include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type-1, and an early-stage research program targeting Huntington's disease. As a clinical-stage entity, the company primarily serves patient populations with these genetic conditions through clinical development and trials.
Company profile, executives and historyDesign Therapeutics stock: common questions
What is Design Therapeutics's stock price?
DSGN closed at $10.58 on Nov 12, 2026, down 1.76% on the day. Over the past 52 weeks it traded between $6.81 and $17.25.
What is Design Therapeutics's market cap?
Design Therapeutics was worth $662.11M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is DSGN's P/E ratio?
Design Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.20), so it has no meaningful P/E ratio.
How much revenue does Design Therapeutics make?
Design Therapeutics reported revenue of $0 for the twelve months to Sep 30, 2026.
Does Design Therapeutics pay a dividend?
No. Design Therapeutics has not paid a cash dividend over the last twelve months.
When does Design Therapeutics report earnings next?
Design Therapeutics is expected to report Q4 FY2026 results on Mar 8, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has DSGN stock performed over the past year?
Including dividends, DSGN returned +39.0% over the past year, against +12.0% for the S&P 500.
How many DSGN shares are sold short?
6M shares were sold short at the latest FINRA report, 12.80% of the float, or 16.2 days of average trading volume.
Who are Design Therapeutics's competitors?
Companies most similar to Design Therapeutics by business, industry and size include TRDA, DYN, IRD, SION, LRMR.
See a number that looks wrong?